Company intelligence / Profile preview

Jilin Huakang Pharmaceutical

Ownership: Private
Development stage: Commercial

Overview

Jilin Huakang Pharmaceutical is a leading Chinese pharmaceutical company with a focus on R&D and manufacturing of both traditional Chinese medicines and modern pharmaceuticals. The company has several products on the market and an active pipeline that includes small molecules and biologics targeting cardiovascular diseases such as angina. Clinical results include ongoing Phase 2/3 studies for key assets like Pseudo-Ginsenoside GQ injection[8].

Therapeutic areas: GastroenterologyCardiovascularImmunology
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

7 assets

xueshuan xinmaining

6 more assets in the full pipeline.

Request access →

Partnerships

No major international pharma partnerships publicly disclosed.

Beyond the preview

Go deeper on Jilin Huakang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jilin Huakang Pharmaceutical.

Explore the full profile